ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

Intellectual Property RightsSubscribe to Intellectual Property Rights

TRIPS and India's Pharmaceuticals Industry

Major changes can be expected in the Indian pharmaceuticals industry from 2005 due to the agreement on TRIPS, under which India will be required to introduce product patents for pharmaceutical products. This will likely lead to sharp increases in the prices of newly patented drugs. Although the TRIPS agreement may also lead to increased research on diseases common in developing countries, these benefits can be obtained in alternative ways, and without high costs. Thus, the TRIPS agreement is not in the national interest and should be renegotiated.

Temporary Reprieve

The US Patent and Trademark Office (USPTO’s) decision on its re-examination of RiceTec’s patents on Basmati rice has once again stirred up parliament – the Lok Sabha had to be adjourned twice – and the media. And, typically, the reactions have run the complete range of emotions and opinions. According to the commerce ministry the commercial interests of Indian exporters of Basmati rice have been fully protected. That, clearly, is not the whole story.

TRIPS Review: Basic Rights Must Be Restored

There is broad consensus that TRIPS in its present form is unacceptable because it violates the fundamental rights of people. Civil society organisations across the world are mobilising opinion to intervene in the TRIPS review process. What are the changes must be negotiated during the current review of TRIPS?

Dwindling International Support for IPRs

Public indignation and dwindling international support for intellectual property rights appear to be forcing powerful MNCs to review their pricing strategy and business models.


Back to Top